Skip to main content
CANbridge Pharmaceuticals Inc. logo

CANbridge Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · 1228 ISIN · KYG1821D1097 LEI · 8755009KKZM9ETBOF853 HKEX Manufacturing
Open in API
Filings indexed 191 across all filing types
Latest filing 2023-06-06 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1228

About CANbridge Pharmaceuticals Inc.

http://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of transformative therapies for rare diseases and rare genetic conditions. The company leverages its foundation in China to deliver life-changing therapeutics globally. Its commercial portfolio includes approved products such as Hunterase® (a recombinant human Enzyme Replacement Therapy) and Livmarli (an oral inhibitor of the ileal bile acid transporter). CANbridge also maintains a pipeline of investigational therapies, including gene therapies, targeting high-impact indications in rare genetic diseases.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities for CANbridge Pharmaceuticals Inc., including authorized and issued share capital, share options, and other share-related movements. It is addressed to the Hong Kong Exchanges and Clearing Limited and pertains to the month ended 31 May 2023. The content focuses on share capital changes and share issuance details rather than financial performance, management commentary, or regulatory certifications. It is not an announcement of a report but a substantive filing about share capital movements. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues and capital changes.
2023-06-06 English
INSIDE INFORMATION ANNOUNCEMENT LIVMARLI (MARALIXIBAT ORAL SOLUTION, CAN108) OBTAINED MARKETING APPROVAL IN CHINA
Regulatory Filings Classification · 95% confidence The document is an announcement made pursuant to the Listing Rules of the Hong Kong Stock Exchange and the Securities and Futures Ordinance. It informs shareholders and potential investors about the marketing approval of a drug (LIVMARLI) in China by the National Medical Products Administration. The document is titled as an "Inside Information Announcement" and contains no financial statements or detailed financial data. It is a regulatory announcement about a significant corporate development (marketing approval) rather than a financial report or detailed presentation. The length is about 4918 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-02 English
CHANGE OF PROCESS AGENT
Regulatory Filings Classification · 100% confidence The document is an announcement from CANbridge Pharmaceuticals Inc. regarding a change of process agent, which is a procedural or administrative update related to the company's authorized representative for legal service in Hong Kong. It does not contain financial data, management changes at the board or senior management level, nor does it relate to shareholder votes, capital changes, or other financial or governance reports. The document is short (1652 characters) and is clearly an announcement of a procedural change rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 April 2023. It details movements in authorized and issued share capital, share options, and other share-related movements for CANbridge Pharmaceuticals Inc. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital changes and share issuance activities. The document is not a financial report, earnings release, or management discussion, but a regulatory filing about share capital movements. It fits the category of Regulatory Filings (RNS) as it is a compliance document reporting share capital movements under exchange rules, not a direct announcement of a share issue or capital change (which would be SHA), nor a director's dealing or share repurchase. The document is about monthly return filings required by the exchange, which is a regulatory filing.
2023-05-05 English
2022 Environmental, Social and Governance Report
Environmental & Social Information Classification · 100% confidence The document is titled 'ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT' and explicitly states it is the second ESG report published by CANbridge Pharmaceuticals Inc. It covers the company's sustainable development strategy, ESG performance, and governance. The report references the ESG Reporting Guide of the Hong Kong Stock Exchange Listing Rules and covers the reporting period from January 1, 2022, to December 31, 2022. It also mentions that the report is disclosed alongside the 2022 Annual Report but is a separate document focusing on ESG factors. The content includes detailed ESG strategy, governance, stakeholder engagement, and materiality assessment, which aligns with the definition of Environmental & Social Information (SR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the appropriate classification is Environmental & Social Information (SR).
2023-04-26 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, JUNE 27, 2023
AGM Information Classification · 95% confidence The document is a Form of Proxy for the Annual General Meeting (AGM) of CANbridge Pharmaceuticals Inc. It includes instructions for shareholders to appoint proxies to vote on resolutions at the AGM, including approval of audited financial statements, re-election of directors, appointment of auditors, and granting mandates related to shares. The document is procedural and related to the AGM meeting arrangements and voting, not the actual AGM materials or presentations. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms and voting materials.
2023-04-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.